Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, July 29, 2009
Tue, July 28, 2009 E-18 Corporation: Protectus Management Profile: Dr. John Salstrom, Seasoned Biotech Executive, Heads Protectus Management Team
MINNEAPOLIS, MN--(Marketwire - July 28, 2009) - E-18 Corp. (
Dr. Salstrom is a co-founder of Protectus Medical Devices, Inc. He has over twenty-eight years of experience with startup companies, mainly in biotechnology and medical technology. He served as Head of the Vector Development Program at Molecular Genetics, Inc., Research Director of the Molecular Biology and Human Healthcare Programs at Endotronics, Inc. and he was a co-founder and Vice President of Scientific Affairs at Helix BioCore, Inc. He also co-founded and served as Director for Ganesh Energene Ltd. (Mumbai), an Indian joint venture company.
Dr. Salstrom is a Microbiologist and Molecular Biologist by training, having received his B.A. from Miami University, his M.S. and Ph.D. degrees from the University of Wisconsin, followed by a Postdoctoral fellowship at Harvard University. He holds numerous academic honors and awards, several U.S. and foreign patents and has to his credit numerous publications, articles, theses and manuscripts. Dr. Salstrom has held several research and teaching positions.
"I am delighted to serve with an outstanding management team at Protectus Medical Devices to bring our innovative products to market," Dr. Salstrom said. "We are passionate about our mission, which is not only to build value for our shareholders, but to potentially save the lives of healthcare workers, who face the possibility of incurring needlestick injuries every day they go to work. These healthcare workers deserve a solution that will truly prevent needlestick injuries, which have tragically affected so many lives and cost our healthcare system billions of dollars annually. We look forward to keeping the public and our shareholders updated regarding the Company's progress."
More information about Protectus Medical Devices may be found at the Company's corporate website at [ www.protectusmedical.com ].
About E-18 Corp.
E-18 Corp., through its wholly owned subsidiary, SquareOne Medical, Inc., doing business as Protectus Medical Devices, develops and markets innovative safety medical percutaneous devices that, collectively, have the potential to dramatically reduce needlestick injuries for medical professionals worldwide. In the nearly $5 billion global hypodermic syringe market, the Protectus Safety Syringe, the Company's lead product, is the only fully automatic, self-sheathing hypodermic safety syringe that currently meets the functional definition of "Self-Sheathing" mandated by the U.S. Federal Government. None of the manufacturers of other devices on the market can make this claim. Protectus Medical Devices has successfully patented its automatic, self-sheathing hypodermic safety syringe product, and, based on the results of full comparison clinical trials, the Protectus Safety Syringe (formerly the SquareOne Safety Syringe) has received the required 510(k) permission from the U.S. FDA to manufacture and market the device in the U.S. More information about the Company may be found at [ www.protectusmedical.com ].
Forward-Looking Statements
Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties. Words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import also identify forward-looking statements. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Additional information on risks and other factors that may affect the business and financial results of E-18 Corp. can be found in the filings of E-18 Corp. with the U.S. Securities and Exchange Commission.
